U.S., July 10 -- ClinicalTrials.gov registry received information related to the study (NCT07057167) titled 'Prediction of Ovarian Cancer Histotypes and Surgical Outcome' on June 27.
Brief Summary: The standard treatment for advanced ovarian cancer (AOC) is primary cytoreductive surgery (PCS) followed by adjuvant chemotherapy. However, optimal cytoreduction is not always achievable, particularly in cases with high tumor burden or patient frailty. In such scenarios, neoadjuvant chemotherapy (NACT) followed by interval cytoreductive surgery (ICS) represents a valid alternative with comparable oncologic outcomes in selected patients.
To optimize surgical strategy, objective tools are needed to identify the best candidates for PCS. Scoring sy...